Patents by Inventor Eun-Hye Jung

Eun-Hye Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240339436
    Abstract: A stack package is provided. The stack package includes a package substrate on which a first bond finger and a second bond finger are spaced apart from each other, and a second semiconductor die stacked over a first semiconductor die. A first connector connects the first semiconductor die to the first bond finger. A second connector connects the second semiconductor die to the second bond finger and extends to have substantially the same length as the first connector.
    Type: Application
    Filed: October 9, 2023
    Publication date: October 10, 2024
    Applicant: SK hynix Inc.
    Inventors: Eun Hye DO, Chang Shik JUNG
  • Patent number: 11655235
    Abstract: The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: May 23, 2023
    Assignee: YUHAN CORPORATION
    Inventors: Tae Han Dong, Yoo Hoi Park, Tae Kyun Kim, Jae Eun Joo, Eun Hye Jung, Jae Won Jeong, Hyun Seung Lee, Do Hoon Kim, Ji Eun Yang, Jun Chui Park, Sang Myoun Lim, Na Ry Ha, Da In Chung, Ji Yeong Gal
  • Patent number: 11492335
    Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: November 8, 2022
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Su Bin Choi, Dong Hoon Kim, Sol Park, Eun Hye Jung, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
  • Publication number: 20210147368
    Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Application
    Filed: November 25, 2020
    Publication date: May 20, 2021
    Inventors: Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Su Bin CHOI, Dong Hoon KIM, Sol PARK, Eun Hye JUNG, Hyun Ho CHOI, Tae Wang KIM, Mi Kyeong JU, Na Ry HA
  • Publication number: 20210147386
    Abstract: The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 20, 2021
    Inventors: Tae Han DONG, Yoo Hoi PARK, Tae Kyun KIM, Jae Eun JOO, Eun Hye Jung, Jae Won JEONG, Hyun Seung LEE, Do Hoon KIM, Ji Eun YANG, Jun Chul PARK, Sang Myoun LIM, Na Ry HA, Da In CHUNG, Ji Yeong GAL
  • Patent number: 10941136
    Abstract: The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: March 9, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Young-Hwan Kim, Tae-Dong Han, Dong-Hoon Kim, Eun-Hye Jung, Su-Bin Choi, Eui-Chul Lee, Won-Ee Chong, Jin-Hwi Park, Jun-Chul Park, Ho-Woong Kang, Ji-Yeong Gal, Chan-Sun Park, Jong-Gyun Kim, Su-Youn Nam
  • Patent number: 10899719
    Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 26, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Su Bin Choi, Dong Hoon Kim, Sol Park, Eun Hye Jung, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
  • Publication number: 20200325120
    Abstract: The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.
    Type: Application
    Filed: April 26, 2017
    Publication date: October 15, 2020
    Applicant: YUHAN CORPORATION
    Inventors: Young-Hwan KIM, Tae-Dong HAN, Dong-Hoon KIM, Eun-Hye JUNG, Su-Bin CHOI, Eui-Chul LEE, Won-Ee CHONG, Jin-Hwi PARK, Jun-Chul PARK, Ho-Woong KANG, Ji-Yeong GAL, Chan-Sun PARK, Jong-Gyun KIM, Su-Youn NAM
  • Publication number: 20200223808
    Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Application
    Filed: December 19, 2019
    Publication date: July 16, 2020
    Inventors: Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Su Bin CHOI, Dong Hoon KIM, Sol PARK, Eun Hye JUNG, Hyun Ho CHOI, Tae Wang KIM, Mi Kyeong JU, Na Ry HA
  • Patent number: 10562865
    Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: February 18, 2020
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Su Bin Choi, Dong Hoon Kim, Sol Park, Eun Hye Jung, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
  • Publication number: 20190308944
    Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Application
    Filed: March 20, 2019
    Publication date: October 10, 2019
    Applicant: YUHAN CORPORATION
    Inventors: Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Su Bin CHOI, Dong Hoon KIM, Sol PARK, Eun Hye JUNG, Hyun Ho CHOI, Tae Wang KIM, Mi Kyeong JU, Na Ry HA
  • Publication number: 20170253717
    Abstract: A conductive thermoplastic resin composition, according to the present invention, comprises a polycarbonate resin and a conductive filler, wherein the conductive filler comprises carbon nanotube-modified glass fibers and/or processed carbon nanotube-modified glass fibers. A conductive thermoplastic resin composition has excellent electrical conductivity, flame retardancy, and mechanical properties.
    Type: Application
    Filed: August 28, 2015
    Publication date: September 7, 2017
    Applicant: LOTTE ADVANCED MATERIALS CO., LTD.
    Inventors: Chan Gyun SHIN, Min Soo LEE, Eun Hye JUNG, Sang Hyun HONG
  • Patent number: 9663495
    Abstract: Provided is a triazolone derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The triazolone derivative or its pharmaceutically acceptable salt can effectively activate GPR119; and therefore be usefully applied for preventing or treating diabetes mellitus.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: May 30, 2017
    Assignee: YUHAN CORPORATION
    Inventors: Tae-Dong Han, Eun-Hye Jung, Chung-Ho Yi, Byoung-Moon Lee, Yoo-Hoi Park, Dong-Hoon Lee, Jong-Ho Kang, Na-Yeon Yang, Do-Hoon Kim, Kwan-Hoon Hyun, Kaap-Joo Park, Chun-Ho Lee, Su-Youn Nam
  • Patent number: 9595364
    Abstract: Provided is a conductive sheet composition including a polycarbonate resin, a rubber-modified vinyl-based graft copolymer, carbon nanotube, and a silicone particle to improve conductivity and mechanical physical properties and reduce surface gloss.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: March 14, 2017
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Eun Hye Jung, Chan Gyun Shin, Jong Cheol Lim, Nam Hyun Kim
  • Patent number: 9376420
    Abstract: The present invention provides a 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt effectively increases the LXR transcriptional activity, and therefore can be usefully applied for preventing or treating a dysfunction in cholesterol metabolism, such as cholesterol gallstone, hyperlipidemia, or coronary atherosclerosis.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 28, 2016
    Assignee: YUHAN CORPORATION
    Inventors: Chan-Sun Park, Young-Hwan Kim, Gyu-Jin Lee, Youn Hur, Eun-Hye Jung, Hee-Jae Tak, Seung-Yub Shin, Ho-Jin Lee, Chun-Ho Lee, Koo-Yeon Lee
  • Publication number: 20160068515
    Abstract: Provided is a triazolone derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The triazolone derivative or its pharmaceutically acceptable salt can effectively activate GPR119; and therefore be usefully applied for preventing or treating diabetes mellitus.
    Type: Application
    Filed: April 22, 2014
    Publication date: March 10, 2016
    Applicant: YUHAN CORPORATION
    Inventors: Tae-Dong HAN, Eun-Hye JUNG, Chung-Ho YI, Byoung-Moon LEE, Yoo-Hoi PARK, Dong-Hoon LEE, Jong-Ho KANG, Na-Yeon YANG, Do-Hoon KIM, Kwan-Hoon HYUN, Kaap-Joo PARK, Chun-Ho LEE, Su-Youn NAM
  • Publication number: 20150291563
    Abstract: The present invention provides a 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 4,5-dihydro-1H-pyrazole derivative or its pharmaceutically acceptable salt effectively increases the LXR transcriptional activity, and therefore can be usefully applied for preventing or treating a dysfunction in cholesterol metabolism, such as cholesterol gallstone, hyperlipidemia, or coronary atherosclerosis.
    Type: Application
    Filed: October 23, 2013
    Publication date: October 15, 2015
    Applicant: YUHAN CORPORATION
    Inventors: Chan-Sun Park, Young-Hwan Kim, Gyu-Jin Lee, Youn Hur, Eun-Hye Jung, Hee-Jae Tak, Seung-Yub Shin, Ho-Jin Lee, Chun-Ho Lee, Koo-Yeon Lee
  • Patent number: D761316
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: July 12, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Sang Hyun Park, Eun Hye Jung
  • Patent number: D771709
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: November 15, 2016
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Eun-Hye Jung, Jung-Sun Jin, Ji-Hye Myung
  • Patent number: D794650
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: August 15, 2017
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Sook-Kyung Lee, Eun-Hye Jung, Ji-Hye Myung, Sang-Hyun Park